ReviewClinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study
Introduction
Anti-synthetase syndrome (ASSD) is a connective disease mainly affecting adults at any age, characterized by a strict association with aminoacyl-transfer RNA synthetase (ARS) antibodies and by a highly variable clinical picture [1]. Interstitial lung disease (ILD), myositis and arthritis represent the classic clinical triad of the disease, with frequencies ranging from 60% to 95% of cases [2], [3], [4], [5], [6], [7], [8]. Recently, it has been shown that in anti-Jo1 positive ASSD, the clinical triad of the disease is rarely observed at disease onset, and that patients presenting with just one or two classic triad findings (for a practical purpose defined as incomplete forms) frequently will develop additional triad features during the follow-up [9], [10], [11]. The later appearance of initially absent classic triad findings during the follow-up is common and, of interest, is particularly increased in patients with a single triad finding onset, depicted in up to 50% of anti-Jo1 positive ASSD [10]. Other ASSD typical clinical features, like fever, Raynaud phenomenon (RP) and mechanic's hands (MHs), are less frequently observed in comparison to the classic triad findings and have been reported in approximately 40% of cases [10], [11], [12]. Although the presence of MHs is a relevant clinical clue for the diagnosis of ASSD [13], the implications and clinical predictive value of the development of fever, MHs and RP during the course of the disease in patients without the classic triad at disease onset have not been evaluated yet. Thus, the aim of this multicenter, international and retrospective study was to assess whether the development of RP, fever or MHs during the follow-up may predict the subsequent occurrence of the baseline absent classic triad manifestations in one of the largest cohort of anti-Jo1 positive ASSD [10].
Section snippets
Patients and methods
Patients were selected from a retrospective large database of ASSD patients regularly followed at twenty-four Rheumatology centers from Italy (14), Spain (6), Germany (3), and USA (1), as previously described [10]. Patients were eligible if they had at least two anti-Jo1 positive tests and presented, at disease onset, with an incomplete ASSD (just one or two findings between arthritis, myositis and ILD). Signed informed consent as approved by the local Institutional Ethics Board was required
Results
One-hundred and sixty-five (123 women, 42 men) with incomplete ASSD were selected. The median age at disease onset was 53 years (IQR 42–64) and the median follow-up 94 months (IQR 49–156).
Discussion
To the best of our knowledge, results of the present study provide the first demonstration that anti-Jo1 positive ASSD patients with incomplete forms at disease onset who during the follow-up develop non-classic accompanying ASSD clinical features have an almost four-fold increased risk for new classic triad manifestation occurrence when compared to those patients who do not develop accompanying features. Indeed, the diagnosis of ASSD is still challenging because symptoms are often non-specific
Take-home messages
- •
Interstitial lung disease, arthritis and myositis represent the classical triad manifestations of anti-synthetase syndrome (ASSD).
- •
The classical triad manifestations are rarely contemporary observed at disease onset and an incomplete form, with one or two classic triad manifestations, characterizes about 80% of patients at disease presentation. Nevertheless, the appearance of the complete classic triad manifestations is common during the follow-up of the disease.
- •
Studies aimed at establishing
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Disclosures: None to declare.
References (28)
- et al.
Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome
Autoimmun Rev
(2012) - et al.
Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity
Autoimmun Rev
(2012) - et al.
The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome
Autoimmun Rev
(2014) - et al.
Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group
Semin Arthritis Rheum
(2016) - et al.
The antisynthetase syndrome
Am J Med
(2011) - et al.
Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome
Eur J Intern Med
(2013) - et al.
Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome
Joint Bone Spine
(2009) Antisynthetase syndrome: a review of etiopathogenesis, diagnosis and management
Curr Med Chem
(2015)- et al.
Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome
PLoS One
(2013) - et al.
Clinical and serological aspects of patients with anti-Jo-1 antibodies-an evolving spectrum of disease manifestations
Clin Rheumatol
(2000)
Clinical heterogeneity and prognostic features of South Australian patients with antisynthetase autoantibodies
Intern Med J
Clinical heterogeneity and outcomes of antisynthetase syndrome
Curr Rheumatol Rep
Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients
Rheumatology
Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study
Medicine
Cited by (44)
Joint and muscle inflammatory disease: A scoping review of the published evidence
2023, Seminars in Arthritis and RheumatismAutoantibodies: Pathogenic or epiphenomenon
2022, Best Practice and Research: Clinical RheumatologyCitation Excerpt :In the AENEAS cohort study of anti-Jo1-positive patients, ILD was present in 50% at disease onset and in 84% after 80-month follow-up [12]. Furthermore, the occurrence of novel clinical manifestations such as fever, Raynaud's phenomenon, and mechanic's hands during follow-up in anti-Jo1-positive patients with incomplete ASyS syndrome was associated with active disease and a predictor of appearance of at least one classical triad manifestation [21]. Among the other components of the triad, myositis has been reported with a higher prevalence in anti-Jo1-positive patients when compared to the other antisynthetase autoantibodies [24].
HLA association with the susceptibility to anti-synthetase syndrome
2021, Joint Bone SpineClinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients
2019, Respiratory MedicineCitation Excerpt :This is a CTD characterized by the presence of the classic triad of myositis, ILD and inflammatory arthritis in which fever, RP, calcinosis, mechanic's hands and cutaneous sclerosis may occur. Patients with Anti tRNA Synthetase antibody positivity plus a non-Usual Interstitial Pneumonia (UIP) pattern in HRCT were considered for IPAF, while patients that also showed other clinical features of critis), were classified for a definite diagnosis [22]. The remaining 45 patients were considered for IPAF.
Anti-synthetase syndrome in a child with pneumomediastinum: a case report and literature review
2024, BMC Pulmonary MedicineCoexistence of Multiple Myositis-Specific Antibodies in Patients with Idiopathic Inflammatory Myopathies
2022, Journal of Clinical Medicine